Contribution of new technologies to characterization and prediction of adverse effects

Critical Reviews in Toxicology

Volumn 45, Issue 2, 2015, Pages 172-183

  Rouquié, David ^a   Heneweer, Marjoke ^b   Botham, Jane ^c   Ketelslegers, Hans ^d   Markell, Lauren ^e   Pfister, Thomas ^f   Steiling, Winfried ^g   Strauss, Volker ^h   Hennes, Christa ⁱ  

^a BAYER AG   (Germany)

^b SHELL GLOBAL SOLUTIONS INTERNATIONAL B V   (United States)

^c JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^d EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^e DUPONT COMPANY   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g HENKEL KGAA   (Germany)

^h BASF SE   (Germany)

ⁱ European Centre for Ecotoxicology and Toxicology of Chemicals   (Belgium)

Author keywords

Adverse effect; In vitro testing; Mode of action; Omics; Predictive toxicology

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ANDROGEN RECEPTOR; ENDOCRINE DISRUPTOR; ESTROGEN RECEPTOR; FLUTAMIDE; FORMALDEHYDE; NAPROXEN; PARAQUAT; PYRETHROID; TRANSCRIPTOME; XENOBIOTIC AGENT;

ADVERSE OUTCOME; ANIMAL WELFARE; BIOAVAILABILITY; CHEMICAL CARCINOGENESIS; CONCENTRATION RESPONSE; DEVELOPMENTAL TOXICITY; ENVIRONMENTAL EXPOSURE; EXPERIMENTAL ANIMAL; EYE IRRITATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLOME; MITOCHONDRIAL TOXICITY; NEUROTOXICITY; NONHUMAN; PATHOLOGY; PREDICTION; QUALITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SCREENING TEST; SKIN SENSITIZATION; STOMACH ULCER; TECHNOLOGY; TOXICITY TESTING; TOXICOKINETICS; TRANSCRIPTOMICS; ANIMAL; ANIMAL TESTING ALTERNATIVE; DRUG SCREENING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; PREDICTIVE VALUE; PROCEDURES; TOXICOGENETICS;

ANIMALIA;

ANIMAL TESTING ALTERNATIVES; ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TOXICITY TESTS; TOXICOGENETICS;

EID: 84922918827     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2014.986054     Document Type: Review

References (97)

1. Adler S, Pellizzer C, Hareng L, Hartung T, Bremer S. (2008). First steps in establishing a developmental toxicity test method based on human embryonic stem cells. Toxicol In Vitro, 22, 200-11
2. Andersen ME, Krewski D. (2010). The vision of toxicity testing in the 21st century: moving from discussion to action. Toxicol Sci, 11, 17-24
3. Andersen ME, Clewell HJ III, Bermudez E, Willson GA, Thomas RS. (2008). Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. Toxicol Sci , 105, 36883
4. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. (2010). Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem, 29, 730-41
5. Aylward LL, Hays SM. (2011). Consideration of dosimetry in evaluation of ToxCast data. J Appl Toxicol, 31, 741-51
6. Balcke GU, Kolle SN, Kamp H, Bethan B, Looser R, Wagner S, et al. 2011. Linking energy metabolism to dysfunctions in mitochondrial respiration - A metabolomics in vitro approach. Toxicol Lett, 203 , 200-9
7. Barrila J, Radtke AL, Crabbe A, Sarker SF, Herbst-Kralovetz MM, Ott CM, Nickerson CA. (2010). Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nat Rev Microbiol, 8, 791-801
8. Bauch C, Kolle SN, Ramirez T, Eltze T, Fabian E, Mehling A, et al. (2012). Putting the parts together: combining in vitro methods to test for skin sensitizing potentials. Regul Toxicol Pharmacol, 63, 489-504
9. Beyer RP, Fry RC, Lasarev MR, McConnachie LA, Meira LB, Palmer VS, et al .; Members of the Toxicogenomics Research Consortium. (2007). Multicenter study of acetaminophen hepatotoxicity reveals the importance of biological endpoints in genomic analyses. Toxicol Sci, 99, 326-37
10. Black MB, Budinsky RA, Dombkowski A, Cukovic D, LeCluyse EL, Ferguson SS. (2012). Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin. Toxicol Sci, 127, 199-215
11. Blaauboer BJ, Barratt MD, Houston JB. (1999). The integrated use of alternative methods in toxicological risk evaluation. ECVAM Integrated Testing Strategies task force report 1. ATLA, 27, 229-237
12. Blaauboer BJ. (2010). Biokinetic modeling and in vitro-in vivo extrapolations. J Toxicol Environ Health B Crit Rev, 13, 242-52
13. Blaauboer BJ, Boekelheide K, Clewell HJ, Daneshian M, Dingemans MML, Goldberg AM, et al. (2012). The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. Altex 29, 411-425
14. Boekelheide K, Campion SN. (2010). Toxicity testing in the 21st century: using the new toxicity testing paradigm to create a taxonomy of adverse eff ects. Toxicol Sci, 114, 20-4
15. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol, 36, 781-92
16. Budinsky RA, Schrenk D, Simon T, Van den Berg M, Reichard JF , Silkworth JB, et al. (2014). Mode of action and dose-response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study. Crit Rev Toxicol, 44, 83-119
17. Bus JS, Becker RA. (2009). Toxicity testing in the 21st century: a view from the chemical industry. Toxicol Sci, 112, 297-302
18. Bushel PR, Heinloth AN, Li J, Huang L, Chou JW, Boorman GA, et al. (2007). Blood gene expression signatures predict exposure levels. Proc Natl Acad Sci USA, 104, 18211-6
19. Casciano DA. (2012). The use of genomics in model in vitro systems. Adv Exp Med Biol, 745, 210-20
20. Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, et al. (2006). Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. ATLA , 34, 49-84
21. Corton JC, Cunningham ML, Hummer BT, Lau C, Meek B, Peters JM , et al. (2014). Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-Activated receptor alpha (PPAR ) as a case study. Crit Rev Toxicol, 44, 1-49
22. Cunningham ML, Irwin R, Boorman G. (2003). Tox/path team takes on diff erential gene expression. Environ Health Perspect, 111, A814-5
23. ECETOC. (2002). Recognition of, and diff erentiation between, adverse and non-Adverse eff ects in toxicology studies. Technical Report No. 85. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels
24. ECETOC. (2006). Toxicological modes of action: Relevance for human risk assessment. Technical Report No. 99. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels
25. ECETOC. (2008). Workshop on the application of omics technologies in toxicology and ecotoxicology: case studies and risk assessment. Workshop Report No. 11. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels
26. ECETOC. (2010). Omics in (eco)toxicology: case studies and risk assessment. Workshop Report No. 19. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels
27. ECETOC. (2013). Omics and risk assessment science. Workshop Report No. 25. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels
28. EDSTAC. (1998). EDSTAC fi nal report, Chapter fi ve, Screening and testing. Endocrine Disruptor Screening and Testing Advisory Committee, US EPA Endocrine Disruptor Screening Program
29. Elcombe CR, Peff er RC, Wolf DC, Bailey J, Bars R, Bell D, et al. (2014). Mode of action and human relevance analysis for nuclear receptormediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit Rev Toxicol, 44 , 64-82
30. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. (2005). Comparison of the expression profi les induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res, 575 , 61-84
31. Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ. (2008). Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-Term in vivo studies. Mutat Res, 637 , 23-39
32. Fannin RD, Russo M, O Connell TM, Gerrish K, Winnike JH, Macdonald J, et al. (2010). Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology, 51, 227-36
33. Forsby A, Blaauboer B. (2007). Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity. Hum Exp Toxicol, 26, 333-8
34. Gant TW, Baus PR, Clothier B, Riley J, Davies R, Judah DJ, et al. (2003). Gene expression profi les associated with infl ammation, fi brosis, and cholestasis in mouse liver after griseofulvin. Environ Health Perspect , 111, 37-43
35. Groothuis FA, Heringa MB, Nicol B, Hermens JLM, Blaauboer BJ , Kramer NI. (2013). Dose metric considerations in in vitro assays to improve quantitative in vitro-in vivo dose extrapolations. Toxicology Aug 23. pii: S0300-483X(13)00231-X. doi: 10.1016/j.tox.2013.08.012. [Epub ahead of print].
36. Gubbels-van Hal WMLG, Blaauboer BJ, Barentsen HM, Hoitink MA, Meerts IATM, van der Hoeven JCM. (2005). An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing. Regul Toxicol Pharmacol, 42, 284-95
37. Hamadeh HK, Knight BL, Haugen AC, Sieber S, Amin RP , Bushel PR, et al. (2002). Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. Toxicol Pathol , 30, 470-82
38. Hamadeh HK, Jayadev S, Gaillard ET, Huang Q, Stoll R, Blanchard K, et al. (2004). Integration of clinical and gene expression endpoints to explore furan-mediated hepatotoxicity. Mutat Res, 549, 169-83
39. Harrill JA, Li Z, Wright FA, Radio NM, Mundy WR, Tornero-Velez R, Crofton KM. (2008). Transcriptional response of rat frontal cortex following acute in vivo exposure to the pyrethroid insecticides permethrin and deltamethrin. BMC Genomics, 9, 546
40. Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fannin RD , Sieber SO, et al. (2004). Gene expression profi ling of rat livers reveals indicators of potential adverse eff ects. Toxicol Sci, 80, 193-202
41. Hill AB. (1965). The environment and disease: association or causation?. Proc R Soc Med, 58, 295-300
42. Hoff mann D, Adler M, Vaidya VS, Rached E, Mulrane L, Gallagher WM, et al. (2010). Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci, 116, 8-22
43. Huh D, Hamilton GA, Ingber DE. (2011). From 3D cell culture to organson-chips. Trends Cell Biol, 21, 745-54
44. Jennen D, Ruiz-Aracama A, Magkoufopoulou C, Peijnenburg A, Lommen A, van Delft J, Kleinjans J. (2011). Integrating transcriptomics and metabonomics to unravel modes-of-Action of 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) in HepG2 cells. BMC Syst Biol, 5, 139
45. Jennings P, Weiland C, Limonciel A, Bloch KM, Radford R, Aschauer L, et al. (2012). Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model. Arch Toxicol, 86, 571-89
46. Juberg DR, Borghoff SJ, Becker RA, Casey W, Hartung T, Holsapple MP, et al. (2014). t 4 Workshop report: Lessons learned, challenges, and opportunities: The U.S. endocrine disruptor screening program. ALTEX, 31, 63-78
47. Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, Mortensen HM, et al. (2010). In vitro screening of environmental chemicals for targeted testing prioritization: The ToxCast Project. Environ Health Perspect, 118, 485-92
48. Jung J, Park M, Park HJ, Shim SB, Cho YH, Kim J, et al. (2011). 1 H NMR-based metabolic profi ling of naproxen-induced toxicity in rats. Toxicol Lett, 200, 1-7
49. Kavlock R, Chandler K, Houck K, Hunter S, Judson R, Kleinstreuer N, et al. (2012). Update on EPA s ToxCast program: providing high throughput decision support tools for chemical risk management. Chem Res Toxicol, 25, 1287-302
50. Keller DA, Juberg DR, Catlin N, Farland WH, Hess FG, Wolf DC , Doerrer NG. (2012). Identifi cation and characterization of adverse eff ects in 21st century toxicology. Toxicol Sci, 126, 291-7
51. Kleinstreuer NC, Smith AM, West PR, Conard KR, Fontaine BR, Weir-Hauptman AM, et al. (2011). Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol, 257, 111-21
52. Kolle SN, Ramirez T, Kamp HG, Buesen R, Flick B, Strauss V, van Ravenzwaay B. (2012). A testing strategy for the identifi cation of mammalian, systemic endocrine disruptors with particular focus on steroids. Regul Toxicol Pharmacol, 63, 259-78
53. Kramer NI, Busser FJM, Oosterwijk MTT, Schirmer K, Escher BI , Hermens JLM. (2010). Development of a partition-controlled dosing system for cell assays Chem Res Toxicol, 23, 1806-4
54. Kramer NI, Krismartina M, Rico-Rico A, Blaauboer BJ, Hermens JLM. (2012). Quantifying processes determining the free concentration of phenanthrene in basal cytotoxicity assays. Chem Res Toxicol, 25 , 436-45
55. Lewis RW, Botham JW. 2013. A review of the mode of toxicity and relevance to humans of the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-1, 3-cyclohexanedione. Crit Rev Toxicol, 43, 185-99
56. Lobenhofer EK, Cui X, Bennett L, Cable PL, Merrick BA, Churchill GA, Afshari CA. (2004). Exploration of low-dose estrogen eff ects: identifi cation of No Observed Transcriptional Eff ect Level (NOTEL). Toxicol Pathol, 32, 482-92
57. Louisse J, de Jong E, van de Sandt JJM, Blaauboer BJ , Woutersen RA, Piersma AH, et al. (2010). The use of in vitro toxicity data and physiologically based kinetic modeling to predict doseresponse curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol Sci, 118, 470-84
58. Louisse J, Bosgra S, Blaauboer BJ, Rietjen IMCM, Verwei M. (2014). Prediction of in vivo developmental toxicity of all-Trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modelling. Arch Toxicol. [Epub ahead of print].
59. Ludwig S, Tinwell H, Schorsch F, Cavaill e C, Pallardy M, Rouqui e D , Bars R. (2011). A molecular and phenotypic integrative approach to identify a no-eff ect dose level for antiandrogen-induced testicular toxicity. Toxicol Sci, 122, 52-63
60. Matheis KA, Com E, Gautier JC, Guerreiro N, Brandenburg A, Gmuender H, et al. (2011). Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers. Toxicol Appl Pharmacol, 252, 112-22
61. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591-653
62. Meek ME, Boobis A, Cote I, Dellarco V, Fotakis G, Munn S, Seed J, Vickers C. (2014a). New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol, 34, 1-18
63. Meek ME, Palermo CM, Bachman AN, North CM, Lewis RJ. (2014b). Mode of action human relevance (MOA/HR) framework-evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. Appl Toxicol, 34, 595-606
64. Moggs JG, Tinwell H, Spurway T, Chang H-S, Pate I, Lim FL, et al. (2004). Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect, 112 , 1589-606
65. Murk AJ, Rijntjes E, Blaauboer BJ, Clewell R, Crofton KM, Dingemans MML, et al. (2013). Mechanism-based testing strategy using in vitro approaches for identifi cation of thyroid hormone disrupting chemicals. Toxicology in Vitro, 27, 1320-46
66. NRC. (2007). Toxicity testing in the 21st century: a vision and a strategy. Committee on Toxicity Testing and Assessment of Environmental Agents, National Research Council. Washington, DC: National Academies Press. Available at: http://www.nap.edu/.catalog/11970.html. [Accessed 1st December 2014].
67. OECD. (2004). OECD Guideline for the Testing of Chemicals 432. In vitro 3T3 NRU phototoxicity test. OECD Paris
68. OECD. (2012). Proposal for a template, and guidance on developing and assessing the completeness of adverse outcome pathways. OECD Paris
69. OECD. (2013). Guideline for the Testing of Chemicals 437. Bovine corneal opacity and permeability test method for identifying i) chemicals inducing serious eye damage and ii) chemicals not requiring classifi cation for eye irritation or serious eye damage. OECD Paris
70. Paules R. (2003). Phenotypic anchoring: linking cause and eff ect. Environ Health Perspect, 111, A338-9
71. Perla V, Perrin NA, Greenlee AR. (2008). Paraquat toxicity in a mouse embryonic stem cell model. Toxicol In Vitro, 22, 515-24
72. Rotroff DM, Dix DJ, Houck KA, Knudsen TB, Martin MT, McLaurin KW, et al. (2012). Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals. Environ Health Perspect, 121, 7-14
73. Rouqui e D, Friry-Santini C, Schorsch F, Tinwell H, Bars R. (2009). Standard and molecular NOAELs for rat testicular toxicity induced by fl utamide. Toxicol Sci, 109, 59-65
74. Rouqui e D, Tinwell H, Blanck O, Schorsch F, Geter D, Wason S, Bars R. 2014. Thyroid Tumor Formation in the Male Mouse Induced by Fluopyram is Mediated by Activation of Hepatic CAR/PXR Nuclear Receptors. Reg Tox and Pharmacol 70, 672-9
75. Ruiz-Aracama A, Peijnenburg A, Kleinjans J, Jennen D, van Delft J, Hellfrisch C, Lommen A. (2011). An untargeted multi-Technique metabolomics approach to studying intracellular metabolites of HepG2 cells exposed to 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin. B MC Genomics, 1 2, 2 51
76. Sawada H, Takami K, Asahi S. (2005). A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci , 83, 282-92
77. Schmidt CW. (2003). Toxicogenomics. Environ Health Perspect, 111 , A20-5
78. Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, et al.; International Programme on Chemical Safety. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol, 34, 146-52
79. Spielmann H, Balls M, Dupuis J, Pape WJ, Pechovitch G, de Silva O , et al. (1998). The International EU/COLIPA in vitro phototoxicity validation study: Results of Phase II (blind trial). Part 1: The 3T3 NRU phototoxicity test. Toxicol In Vitro, 12, 305-27
80. Strigun A, Wahrheit J, Beckers S, Heinzle E, Noor F. (2011). Metabolic profi ling using HPLC allows classifi cation of drugs according to their mechanisms of action in HL-1 cardiomyocytes. Toxicol Appl Pharmacol, 252, 183-91
81. Sturla SJ, Boobis AR, FitzGerald RE, Hoeng J, Kavlock RJ, Schirmer K, et al. (2014). Systems toxicology: from basic research to risk assessment. Chem Res Toxicol, 27, 314-29
82. Tice RR, Austin CP, Kavlock RJ, Bucher JR. (2013). Improving the human hazard characterization of chemicals: a Tox21 update. Environ Health Perspect, 121, 756-65
83. Tinwell H, Rouqui e D, Schorsch F, Geter D, Wason S, Bars R. 2014. Liver Tumor Formation in Female Rat Induced by Fluopyram is Mediated by CAR/PXR Nuclear Receptor Activation. Reg Tox Pharmacol 70 , 647-57
84. Thomas RS, Clewell HJ III, Allen BC, Wesselkamper SC, Wang NCY , Lambert JC, et al. (2011). Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci, 120, 194-205
85. Thomas RS, Clewell HJ III, Allen BC, Yang L, Healy E, Andersen ME. (2012). Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a fi ve chemical case study. Mutat Res, 746 , 135-43
86. Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, et al. (2013). Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a datadriven framework. Toxicol Sci, 136, 4-18
87. van Dartel DAM, Pennings JL, Hendriksen PJ, van Schooten FJ , Piersma AH. (2009). Early gene expression changes during embryonic stem cell diff erentiation into cardiomyocytes and their modulation by monobutyl phthalate. Reprod Toxicol, 27, 93-102
88. van Ravenzwaay B, Herold M, Kamp H, Kapp MD, Fabian E, Looser R, et al. (2012). Metabolomics: a tool for early detection of toxicological eff ects and an opportunity for biology based grouping of chemicalsfrom QSAR to QBAR. Mutat Res, 746, 144-50
89. van Ravenzwaay B, Montoya GA, Fabian E, Herold M, Krennrich G, Looser R, et al. (2014). The sensitivity of metabolomics versus classical regulatory toxicology from a NOAEL perspective. Toxicol Lett, 227, 20-8
90. van Vliet E. (2007). Novel in vitro approaches for the detection of acute neurotoxicity using emerging technologies. Dissertation, University of Konstanz
91. van Vliet E, Morath S, Eskes C, Linge J, Rappsilber J, Honegger P, et al. (2008). A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caff eine. Neurotoxicology, 29, 1-12
92. Vandebriel RJ, Pennings JLA, Baken KA, Pronk TE, Boorsma A, Gottschalk R, Van Loveren H. (2010). Keratinocyte gene expression profi les discriminate sensitizing and irritating compounds. Toxicol Sci, 117 , 81-9
93. Verwei M, van Burgsteden JA, Krul CA, van de Sandt JJ, Freidig AP. (2006). Prediction of in vivo embryotoxic eff ect levels with a combination of in vitro studies and PBPK modelling. Toxicol Lett, 165 , 79-87
94. Vinken M, Whelan M, Rogiers V. (2014). Adverse outcome pathways: hype or hope?. Arch Toxicol, 88, 1-2
95. West PR, Weir AM, Smith AM, Donley EL, Cezar GG. (2010). Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol, 247, 18-27
96. Wilmes A, Limonciel A, Aschauer L, Moenks K, Bielow C, Leonard MO, et al. (2013). Application of integrated transcriptomic, proteomic and metabolomic profi ling for the delineation of mechanisms of drug induced cell stress. J Proteomics, 79, 180-94
97. Yoon M, Efremenko A, Blaauboer BJ, Clewell HJ. (2014). Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. Toxicology in Vitro, 28, 164-70